Cargando…

Investigating fractional exhaled nitric oxide (FeNO) in chronic obstructive pulmonary disease (COPD) and asthma–COPD overlap (ACO): a scoping review protocol

INTRODUCTION: During the last decade, many articles have been published, including reviews on fractional exhaled nitric oxide (FeNO) use and utility in clinical practice and for monitoring and identifying eosinophilic airway inflammation, especially in asthma, and evaluating corticosteroid responsiv...

Descripción completa

Detalles Bibliográficos
Autores principales: Mostafavi-Pour-Manshadi, Seyed-Mohammad-Yousof, Naderi, Nafiseh, Barrecheguren, Miriam, Dehghan, Abolfazl, Bourbeau, Jean
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5778315/
https://www.ncbi.nlm.nih.gov/pubmed/29273668
http://dx.doi.org/10.1136/bmjopen-2017-018954
_version_ 1783294334706122752
author Mostafavi-Pour-Manshadi, Seyed-Mohammad-Yousof
Naderi, Nafiseh
Barrecheguren, Miriam
Dehghan, Abolfazl
Bourbeau, Jean
author_facet Mostafavi-Pour-Manshadi, Seyed-Mohammad-Yousof
Naderi, Nafiseh
Barrecheguren, Miriam
Dehghan, Abolfazl
Bourbeau, Jean
author_sort Mostafavi-Pour-Manshadi, Seyed-Mohammad-Yousof
collection PubMed
description INTRODUCTION: During the last decade, many articles have been published, including reviews on fractional exhaled nitric oxide (FeNO) use and utility in clinical practice and for monitoring and identifying eosinophilic airway inflammation, especially in asthma, and evaluating corticosteroid responsiveness. However, the exact role of FeNO in patients with chronic obstructive pulmonary disease (COPD) and its ability to distinguish patients with COPD and those having concomitant asthma, that is, asthma–COPD overlap (ACO) is still unclear and needs to be defined. Due to the broad topics of FeNO in chronic airway disease, we undertook a scoping review. The present article describes the protocol of a scoping review of peer-reviewed published literature specific to FeNO in COPD/ACO over the last decade. METHODS AND ANALYSIS: We used Joanna Briggs Institute Reviewers’ Manual scoping review methodology as well as Levac et al’s and Arksey et al’s framework as guides. We searched a variety of databases, including Medline, Embase, Cumulative Index to Nursing and Allied Health Literature (CINAHL), Cochrane Library, Web of Science, and BioSciences Information Service (BIOSIS) on 29 June 2016. Additional studies will be recognised by exploring the reference list of identified eligible studies. Screening of eligible studies will be independently performed by two reviewers and any disagreement will be solved by the third reviewer. We will analyse the gathered data from article bibliographies and abstracts. ETHICS AND DISSEMINATION: To investigate the body of published studies regarding the role of FeNO in patients with COPD and its usefulness in the clinical setting, a scoping review can be used as a modern and pioneer model, which does not need ethics approval. By this review, new insights for conducting new research specific to FeNO in COPD/ACO population will emerge. The results of this study will be reported in the scientific meetings and conferences, which aim to provide information to the clinicians, primary care providers and basic science researchers.
format Online
Article
Text
id pubmed-5778315
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-57783152018-01-31 Investigating fractional exhaled nitric oxide (FeNO) in chronic obstructive pulmonary disease (COPD) and asthma–COPD overlap (ACO): a scoping review protocol Mostafavi-Pour-Manshadi, Seyed-Mohammad-Yousof Naderi, Nafiseh Barrecheguren, Miriam Dehghan, Abolfazl Bourbeau, Jean BMJ Open Respiratory Medicine INTRODUCTION: During the last decade, many articles have been published, including reviews on fractional exhaled nitric oxide (FeNO) use and utility in clinical practice and for monitoring and identifying eosinophilic airway inflammation, especially in asthma, and evaluating corticosteroid responsiveness. However, the exact role of FeNO in patients with chronic obstructive pulmonary disease (COPD) and its ability to distinguish patients with COPD and those having concomitant asthma, that is, asthma–COPD overlap (ACO) is still unclear and needs to be defined. Due to the broad topics of FeNO in chronic airway disease, we undertook a scoping review. The present article describes the protocol of a scoping review of peer-reviewed published literature specific to FeNO in COPD/ACO over the last decade. METHODS AND ANALYSIS: We used Joanna Briggs Institute Reviewers’ Manual scoping review methodology as well as Levac et al’s and Arksey et al’s framework as guides. We searched a variety of databases, including Medline, Embase, Cumulative Index to Nursing and Allied Health Literature (CINAHL), Cochrane Library, Web of Science, and BioSciences Information Service (BIOSIS) on 29 June 2016. Additional studies will be recognised by exploring the reference list of identified eligible studies. Screening of eligible studies will be independently performed by two reviewers and any disagreement will be solved by the third reviewer. We will analyse the gathered data from article bibliographies and abstracts. ETHICS AND DISSEMINATION: To investigate the body of published studies regarding the role of FeNO in patients with COPD and its usefulness in the clinical setting, a scoping review can be used as a modern and pioneer model, which does not need ethics approval. By this review, new insights for conducting new research specific to FeNO in COPD/ACO population will emerge. The results of this study will be reported in the scientific meetings and conferences, which aim to provide information to the clinicians, primary care providers and basic science researchers. BMJ Publishing Group 2017-12-21 /pmc/articles/PMC5778315/ /pubmed/29273668 http://dx.doi.org/10.1136/bmjopen-2017-018954 Text en © Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2017. All rights reserved. No commercial use is permitted unless otherwise expressly granted. This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
spellingShingle Respiratory Medicine
Mostafavi-Pour-Manshadi, Seyed-Mohammad-Yousof
Naderi, Nafiseh
Barrecheguren, Miriam
Dehghan, Abolfazl
Bourbeau, Jean
Investigating fractional exhaled nitric oxide (FeNO) in chronic obstructive pulmonary disease (COPD) and asthma–COPD overlap (ACO): a scoping review protocol
title Investigating fractional exhaled nitric oxide (FeNO) in chronic obstructive pulmonary disease (COPD) and asthma–COPD overlap (ACO): a scoping review protocol
title_full Investigating fractional exhaled nitric oxide (FeNO) in chronic obstructive pulmonary disease (COPD) and asthma–COPD overlap (ACO): a scoping review protocol
title_fullStr Investigating fractional exhaled nitric oxide (FeNO) in chronic obstructive pulmonary disease (COPD) and asthma–COPD overlap (ACO): a scoping review protocol
title_full_unstemmed Investigating fractional exhaled nitric oxide (FeNO) in chronic obstructive pulmonary disease (COPD) and asthma–COPD overlap (ACO): a scoping review protocol
title_short Investigating fractional exhaled nitric oxide (FeNO) in chronic obstructive pulmonary disease (COPD) and asthma–COPD overlap (ACO): a scoping review protocol
title_sort investigating fractional exhaled nitric oxide (feno) in chronic obstructive pulmonary disease (copd) and asthma–copd overlap (aco): a scoping review protocol
topic Respiratory Medicine
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5778315/
https://www.ncbi.nlm.nih.gov/pubmed/29273668
http://dx.doi.org/10.1136/bmjopen-2017-018954
work_keys_str_mv AT mostafavipourmanshadiseyedmohammadyousof investigatingfractionalexhalednitricoxidefenoinchronicobstructivepulmonarydiseasecopdandasthmacopdoverlapacoascopingreviewprotocol
AT naderinafiseh investigatingfractionalexhalednitricoxidefenoinchronicobstructivepulmonarydiseasecopdandasthmacopdoverlapacoascopingreviewprotocol
AT barrechegurenmiriam investigatingfractionalexhalednitricoxidefenoinchronicobstructivepulmonarydiseasecopdandasthmacopdoverlapacoascopingreviewprotocol
AT dehghanabolfazl investigatingfractionalexhalednitricoxidefenoinchronicobstructivepulmonarydiseasecopdandasthmacopdoverlapacoascopingreviewprotocol
AT bourbeaujean investigatingfractionalexhalednitricoxidefenoinchronicobstructivepulmonarydiseasecopdandasthmacopdoverlapacoascopingreviewprotocol